Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05115474 · ClinicalTrials.gov registry record
Study of Screening Brain MRIs in Stage IV Breast Cancer
A clinical trial of Triple Negative Breast Cancer and HER2-positive Breast Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- 170
- Enrollment target
- 2
- Study locations
NCT05115474 is a study of Triple Negative Breast Cancer and HER2-positive Breast Cancer that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 170 participants, below the 245-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (31% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05115474, a study of Triple Negative Breast Cancer and HER2-positive Breast Cancer, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- 170 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study is a single arm, nonrandomized phase II prospective study, with the goal of investigating the role of screening brain MRIs in neurologically asymptomatic patients with metastatic breast cancer.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Magnetic Resonance Imaging
Study Locations (2)
Florida
- Morton Plant Mease- Baycare - Clearwater
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2021-12-21 |
| Est. Completion | 2026-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05115474
The ClinicalTrials.gov registry entry for NCT05115474 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (31% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Magnetic Resonance Imaging is the first listed.
NCT05115474 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05115474 about?
NCT05115474 is a clinical study titled "Study of Screening Brain MRIs in Stage IV Breast Cancer". The study is a single arm, nonrandomized phase II prospective study, with the goal of investigating the role of screening brain MRIs in neurologically asymptomatic patients with metastatic breast cancer.
What is the current status of trial NCT05115474?
This trial is currently recruiting. The enrollment target is 170 participants. The study started on 2021-12-21. Estimated completion is 2026-10.
What conditions does trial NCT05115474 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer.
What interventions are being tested in trial NCT05115474?
The interventions under investigation include: Magnetic Resonance Imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05115474?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05115474 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients
RECRUITING · Phase 2
-
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.